Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

DuPont Pioneer and Vilnius University announce CRISPR-Cas patent grantqrcode

May. 3, 2017

Favorites Print
May. 3, 2017

United States  United States

May 2, DuPont Pioneer and Vilnius University confirmed that the United States Patent and Trademark Office granted U.S. Patent Number 9,637,739 to Vilnius University for its broad claims relating to CRISPR-Cas technology. A team of scientists, led by Professor Virginijus Siksnys, from the Vilnius University Institute of Biotechnology was one of the first groups to discover that Cas9 proteins could be repurposed to precisely edit targeted sections of DNA to achieve a specific outcome.

"Our team is very pleased to receive a U.S. patent in recognition of our pioneering work demonstrating that Cas9 functions as a programmable nuclease for gene editing applications," said Siksnys.

"We congratulate Dr. Siksnys and the Institute of Biotechnology of Vilnius University for being awarded this patent which acknowledges significant contributions to the CRISPR-Cas field," said Neal Gutterson, vice president, Research and Development for DuPont Pioneer, the advanced plant genetics business of DuPont. "The Vilnius intellectual property is an important part of our IP portfolio for the use of CRISPR-Cas technology in agriculture."

The Vilnius patent claims are directed to methods of using CRISPR-Cas9 complexes assembled in vitro for site-specific modification of target DNA sequences. CRISPR-Cas9 complexes, referred to as CRISPR ribonucleoproteins or "RNPs," are contemplated for use in a wide variety of gene editing applications, including agriculture, industrial biosciences and therapeutic fields.

DuPont previously announced receiving exclusive rights to the Vilnius intellectual property (IP) for all commercial uses through a technology license from the university. The parties also are engaged in a multi-year research collaboration agreement to further the technical and commercial utility of CRISPR-Cas technology.

DuPont and Caribou Biosciences, Inc. subsequently announced the cross-licensing of their respective patent portfolios.

The DuPont patent estate comprises more than 60 patents and patent applications related to the use of CRISPR for bacteria identification and immunization. It also comprises patent applications related to CRISPR-Cas gene editing technology.

Pioneer is applying CRISPR-Cas as an advanced plant breeding tool to develop seed products for greater environmental resiliency, productivity and sustainability. Pioneer has defined CRISPR-Cas guiding principles which include helping enable others wanting to develop agricultural products using CRISPR-Cas by providing access to its IP, technology capabilities, infrastructure and scientific expertise.

Vilnius University (VU) has been an integral part of European education, scientific and cultural life since its establishment in 1579. VU actively participates in international scientific and academic activities, showing excellence in research and education. For additional information about VU please visit http://www.vu.lt/en. The Institute of Biotechnology (IBT) at Vilnius University is involved in research and training in the fields of biotechnology and molecular biology and serves as the locomotive of biomedical research in Lithuania. For additional information about IBT please visit http://www.ibt.lt/en/title.html


More from AgroNewsChange

Hot Topic More

I wanna post a press Comment


Subscribe Email: *
Mobile Number:  





Subscribe AgroNews Daily Alert to send news related to your mailbox